Post by Journal of Molecular Pathology MDPI

821 followers

šŸš€ #NewPublication in #JMPMDPI ā‡ š‘Ø š‘µš’‚š’“š’“š’‚š’•š’Šš’—š’† š‘Øš’‘š’‘š’“š’š’‚š’„š’‰ š’•š’ š‘“š’Šš’”š’Žš’‚š’•š’„š’‰ š‘¹š’†š’‘š’‚š’Šš’“-š‘«š’†š’‡š’Šš’„š’Šš’†š’š’• š‘¬š’š’…š’š’Žš’†š’•š’“š’Šš’‚š’ š‘Ŗš’‚š’š’„š’†š’“ ā‡ ā™¦āž¤ This narrative review integrates the biological and molecular basis of tumors with recent advances in diagnostic techniques, therapeutic opportunities, and the genomic and phenotypic alterations underlying resistance mechanisms. Special attention is given to the need for robust, clinically affordable biomarkers to promptly identify responders and non-responders to current treatment regimens. āœļø Authors: Massimo Barberis | Yinxiu Zhan Istituto Europeo di Oncologia, IRCCS, Milan, Italy šŸ“„ Read the full paper: https://lnkd.in/d--ciX4i #EndometrialCancer #dMMR #MSIHigh #Immunotherapy #CancerResearch #MolecularPathology

Post content